glycine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ixazomib is a selective and reversible inhibitor of the proteasome, which has been mainly investigated in the treatment of multiple myeloma." | 2.87 | Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). ( Balic, M; Bartsch, R; Burgstaller, S; Egle, D; Fuchs, D; Gampenrieder, SP; Greil, R; Melchardt, T; Mlineritsch, B; Petru, E; Petzer, A; Rinnerthaler, G; Rossmann, D; Rumpold, H; Singer, CF; Ulmer, H, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rinnerthaler, G | 1 |
| Gampenrieder, SP | 1 |
| Petzer, A | 1 |
| Burgstaller, S | 1 |
| Fuchs, D | 1 |
| Rossmann, D | 1 |
| Balic, M | 1 |
| Egle, D | 1 |
| Rumpold, H | 1 |
| Singer, CF | 1 |
| Bartsch, R | 1 |
| Petru, E | 1 |
| Melchardt, T | 1 |
| Ulmer, H | 1 |
| Mlineritsch, B | 1 |
| Greil, R | 1 |
| Zagouri, F | 1 |
| Sergentanis, TN | 1 |
| Chrysikos, D | 1 |
| Papadimitriou, CA | 1 |
| Dimopoulos, MA | 1 |
| Psaltopoulou, T | 1 |
| Noh, S | 1 |
| Kim, DH | 1 |
| Jung, WH | 1 |
| Koo, JS | 1 |
| Kung, PP | 1 |
| Martinez, R | 1 |
| Zhu, Z | 1 |
| Zager, M | 1 |
| Blasina, A | 1 |
| Rymer, I | 1 |
| Hallin, J | 1 |
| Xu, M | 1 |
| Carroll, C | 1 |
| Chionis, J | 1 |
| Wells, P | 1 |
| Kozminski, K | 1 |
| Fan, J | 1 |
| Guicherit, O | 1 |
| Huang, B | 1 |
| Cui, M | 1 |
| Liu, C | 1 |
| Huang, Z | 1 |
| Sistla, A | 1 |
| Yang, J | 1 |
| Murray, BW | 1 |
| Zhang, X | 1 |
| Bai, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer[NCT02993094] | Phase 1/Phase 2 | 31 participants (Actual) | Interventional | 2016-11-21 | Terminated (stopped due to Due to slow recruitment, the study had to be terminated prematurely.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for glycine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Hsp90 inhibitors in breast cancer: a systematic review.
Topics: Adenine; Antineoplastic Agents; Benzamides; Benzoquinones; Biomarkers, Tumor; Female; Glycine; HSP70 | 2013 |
1 trial available for glycine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Boron Compounds; Bortezomib; C | 2018 |
3 other studies available for glycine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues.
Topics: Adult; Aged; Female; Glycine; Glycine Hydroxymethyltransferase; Humans; Middle Aged; Phosphoglycerat | 2014 |
Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chr | 2014 |
Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Chromatography, Liquid; | 2016 |